Xiaokui Mo

Research Scientist

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Lysosomes are critical for maintaining cellular homeostasis and nutrient availability, yet how tumor cells survive under lysosomal inhibition remains unclear. Here, we revealed that inhibiting lysosome function with chloroquine unexpectedly stimulated glucose uptake across various cancer cells. This effect was driven by sterol regulatory element–binding protein 1 (SREBP-1), a key lipogenic transcription factor, which specifically increased the expression of glucose transporters GLUT3 and GLUT6, enhancing glucose uptake and macromolecule synthesis. Elevated glucose, induced by chloroquine, stabilized SREBP cleavage-activating protein (SCAP), the activator of SREBP-1, further amplifying its activity and contributing to tumor resistance to lysosome inhibition. Disrupting this SREBP-1–glucose uptake feedforward loop by combining chloroquine with inhibitors of glucose transporters, SREBP-1, or lipogenic enzymes induced a synergistic antitumor effect in squamous cell and adenocarcinoma lung cancer patient-derived organoids and xenografts. This combination impaired mitochondrial structure and function, inducing apoptotic tumor cell death. Our study uncovers a role for SREBP-1 in regulating glucose metabolism and provides a promising therapeutic strategy that combines lysosome inhibition with glucose transporter or lipogenic enzyme inhibition for effective cancer treatment.

Year:

2026

Elevated hexosamine biosynthesis fuels tumor growth by facilitating protein and lipid glycosylation. But which enzyme in this pathway is better to serve as an antitumor target remains unclear. Here, we revealed that targeting GFAT1, the rate-limiting enzyme in hexosamine synthesis, exhibits limited inhibitory effects on glioblastoma (GBM), the most lethal brain tumor. This outcome is due to the compensation of NAGK-mediated hexosamine salvage pathway. Unexpectedly, inhibiting PGM3, which controls the flux of both de novo hexosamine synthesis and salvage pathways, down-regulates the expression of other enzymes in this pathway and suppresses SREBP-1, a critical lipogenic transcription factor, effectively inhibiting GBM growth. Unexpectedly, SREBP-1 transcriptionally up-regulates the expression of hexosamine synthesis enzymes, while inhibition of these enzymes in turn down-regulates SREBP-1 activation via reducing N-glycosylation of its transporter, SCAP. Our study identified PGM3 as a promising target for treating GBM. Its inhibition disrupts the SREBP-1 activation-hexosamine synthesis positive feedback regulation to effectively eliminate GBM cells.

Year:

2025

The incidence of colorectal cancer in young adults (age of diagnosis <50 years) has been rapidly increasing. Although ∼20% of early-onset colorectal cancer (EOCRC) cases are due to germline mutations, the etiology of the majority of EOCRC cases remains poorly understood. Nongenetic factors such as environmental exposure and lifestyle changes are likely to have a direct link to the increased incidence of sporadic EOCRC. We hypothesize that such factors may be observable as alterations in the epigenome, microbiome, and immunome. We characterized the DNA methylation (DNAm) signature and measured DNAm age in EOCRC by using The Cancer Genome Atlas (TCGA). Furthermore, we carefully identified intratumoral microbes from TCGA and the Oncology Research Information Exchange Network datasets and then related the microbes to deconvolved immune cell abundances in EOCRC. We observed that the DNAm age in the EOCRC cohort was 12 years older when compared with the average-onset colorectal cancer (AOCRC) cohort, using three different epigenetic clocks. Differentially methylated sites associated with gene expression include cAMP-responsive element binding protein signaling in neurons, G protein–coupled receptor signaling, phagosome formation, and S100 family signaling. These differences were validated in the gene expression data from TCGA and the Oncology Research Information Exchange Network. When comparing the intratumoral microbes between EOCRC and AOCRC, no consistent differences were observed. Interestingly, the most abundant microbes interacted with the immune systems differently between the EOCRC and AOCRC tumors, characterized by more and larger positive correlations in EOCRC. These data suggest that epigenetic modulation and accelerated aging may play a key role in the development of EOCRC. Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.

Year:

2025

The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.

Year:

2025

Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.

Year:

2025

Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.

Year:

2025

Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.

Year:

2025

Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.

Year:

2025

Ozone (O3) is an air pollutant that induces pulmonary inflammation and injury, leading to increased susceptibility and exacerbation of chronic lung diseases. Furthermore, ambient O3 concentrations are expected to rise with increasing global temperatures. Docosahexaenoic acid (DHA) is an omega-3 polyunsaturated fatty acid found primarily in oily fish that reduces inflammation and enhances the resolution of inflammation. This is attributed partially to DHA-derived oxylipins termed specialized proresolving mediators that have antiinflammatory and/or proresolving properties. However, whether dietary DHA protects the lungs from O3-induced inflammation and injury is unclear. We hypothesized that dietary DHA supplementation increases pulmonary specialized proresolving mediators and thereby decreases O3-induced pulmonary inflammation. To test this, C57BL/6J mice were fed a control diet or a DHA-enriched diet (2% kcal from DHA) for 6 weeks, exposed to filtered air or 1 ppm O3 for 3 hours (comparable with an O3 action day for humans), and necropsied 24 or 48 hours after exposure. DHA supplementation reduced airspace neutrophilia, decreased cytokine production, and promoted transcriptomic signatures for leukocyte chemotaxis and fatty acid oxidation. Furthermore, dietary DHA increased pulmonary DHA and its oxylipins while decreasing proinflammatory omega-6 polyunsaturated fatty acids and their oxylipins. Oropharyngeal aspiration of DHA oxylipins monohydroxylated 14-hydroxy-DHA and maresin 1 decreased O3-induced airspace neutrophilia and reduced bone marrow–derived macrophage production of neutrophil chemokines Cxcl1 and Cxcl2. These findings reveal that dietary DHA protects the lungs from O3 exposure by driving monohydroxylated 14-hydroxy-DHA and maresin 1 production, which reduces neutrophil-recruiting chemokine production by macrophages. This pathway highlights a potential therapeutic dietary approach for mitigating air pollution–induced pulmonary inflammation.

Year:

2025

Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role has not been elucidated. We describe here a role for Siglec-6 in migration and adhesion of CLL B cells to CLL- bone marrow stromal cells (BMSCs) in vitro and compromised migration to bone marrow and spleen in vivo. Mass spectrometry analysis revealed interaction of Siglec-6 with DOCK8, a guanine nucleotide exchange factor. Stimulation of MEC1-002 CLL cells with a Siglec-6 ligand, sTn, results in Cdc42 activation, WASP protein recruitment and F-actin polymerization, which are all associated with cell migration. Therapeutically, a Siglec-6/CD3-bispecific T-cell-recruiting antibody (T-biAb) improves overall survival in an immunocompetent mouse model and eliminates CLL cells in a patient derived xenograft model. Our findings thus reveal a migratory role for Siglec-6 in CLL, which can be therapeutically targeted using a Siglec-6 specific T-biAb.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (37)

Xiang Zhang

Professor

University of Louisville

UNITED STATES
View details

Eric Singer

Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Jiangjiang Zhu

Ohio State University

UNITED STATES
View details

David Carbone

Ohio State University Medical Center

UNITED STATES
View details

Gregory Riedlinger

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Nicholas Denko

Professor

Ohio State University

UNITED STATES
View details

Kymberly M Gowdy

Associate Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Aik Choon Tan

Senior Director of Data Science

Huntsman Cancer Institute

UNITED STATES
View details

Jenifer Fenton

Professor

Michigan State University

UNITED STATES
View details

Junran Zhang

-

UNITED STATES
View details

Robert Tighe

Associate Professor

Duke Medicine

UNITED STATES
View details

Megan N. Ballinger

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Ning Jin

Associate Proffessor

Ohio State University

UNITED STATES
View details

Martin D. McCarter

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Carlos HF Chan

Emory University

UNITED STATES
View details

Matthew McFadden

The Ohio State University

UNITED STATES
View details

Matthew Kalady

Professor

Ohio State University

UNITED STATES
View details

Etienne Lefai

Research Director

INRA Centre Clermont-Ferrand-Theix-Lyon

FRANCE
View details

Christoph Rader

University of Florida

UNITED STATES
View details

John D. Carpten

City of Hope Comprehensive Cancer Center

UNITED STATES
View details

Alexandra Ikeguchi

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rebecca Dodd

Assistant Professor

The University of Iowa

UNITED STATES
View details

Gabriel Tinoco

Associate Professor of Medicine

Ohio State University

UNITED STATES
View details

Natarajan Muthusamy

Professor of Medicine

Ohio State University

UNITED STATES
View details

Anjun Ma

Assistant Professor

Ohio State University

UNITED STATES
View details

Sheetal Hardikar

University of Utah

UNITED STATES
View details

Qi-En Wang

Professor

The Ohio State University Wexner Medical Center

UNITED STATES
View details

Qin Ma

Vice Chair for Research

Ohio State University

UNITED STATES
View details

Yousef Zakharia

Mayo Clinic Arizona

UNITED STATES
View details

Saame Shaikh

University of North Carolina at Chapel Hill

UNITED STATES
View details

Dan Spakowicz

Assistant Professor

The Ohio State University Comprehensive Cancer Center

UNITED STATES
View details

Daniel W. Rosenberg

University of Connecticut Health Center

UNITED STATES
View details

Xianlin Han

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Arnab Chakravarti

Chair and Professor

Ohio State University

UNITED STATES
View details

Ahmad Tarhini

Senior Member, Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Caroline Dravillas

Ohio State University

UNITED STATES
View details

YunZhou Liu

Ohio State University

UNITED STATES
View details